Payment overview · 2025
General Payments
$641.20
32 reported records · 22 companies
Healthcare provider profile · identity verified
Marcus Earle, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · NEW BERN, NC · NPI 1417290255
Verified facts
What the public records show
CMS Open Payments records show Marcus Earle, D.O. received $641.20 in general payments during 2025 across 32 reported records.
ABBVIE INC. accounted for 15.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $96.72 | 15.1% | 5 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $81.57 | 12.7% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $48.45 | 7.6% | 2 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $46.53 | 7.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.68 | 6.7% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $31.03 | 4.8% | 1 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $30.05 | 4.7% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $27.20 | 4.2% | 1 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $27.01 | 4.2% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $23.42 | 3.6% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $20.01 | 3.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.74 | 2.9% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $17.53 | 2.7% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $16.58 | 2.6% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $16.22 | 2.5% | 1 | 2025 |
| InSightec,Inc | Unresolved — no canonical attribution shown | $16.19 | 2.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.43 | 2.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.12 | 2.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.76 | 2.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$13.59 | 2.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.26 | 2.1% | 1 | 2025 |
| The Binding Site Inc. | Unresolved — no canonical attribution shown | $11.11 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $641.20 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $96.72 | 5 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $81.57 | 3 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $48.45 | 2 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $46.53 | 2 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $31.03 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $27.20 | 1 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $27.01 | 1 | 2025 |
Source payment records
|
|||||
| HADLIMA Normalized: hadlima |
Drug | Organon LLC | $23.42 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| Exablate Normalized: exablate |
Device | InSightec,Inc | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.26 | 1 | 2025 |
Source payment records
|
|||||
| Freelite Normalized: freelite |
Device | The Binding Site Inc. | $11.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
70 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 556 | 132 |
| Amlodipine Besylate | Amlodipine Besylate | 379 | 103 |
| Losartan Potassium | Losartan Potassium | 344 | 85 |
| Omeprazole | Omeprazole | 319 | 77 |
| Lisinopril | Lisinopril | 318 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 299 | 76 |
| Metformin Hcl | Metformin Hcl | 248 | 67 |
| Sertraline Hcl | Sertraline Hcl | 223 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 219 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 187 | 46 |
| Alendronate Sodium | Alendronate Sodium | 181 | 43 |
| Simvastatin | Simvastatin | 168 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 148 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 148 | 42 |
| Trazodone Hcl | Trazodone Hcl | 130 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 127 | 34 |
| Furosemide | Furosemide | 124 | 37 |
| Allopurinol | Allopurinol | 116 | 29 |
| Meloxicam | Meloxicam | 115 | 38 |
| Gabapentin | Gabapentin | 105 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 23 |
| Metformin Hcl Er | Metformin Hcl | 103 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 91 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 26 |
| Montelukast Sodium | Montelukast Sodium | 80 | 26 |
| Carvedilol | Carvedilol | 79 | 20 |
| Potassium Chloride | Potassium Chloride | 76 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | suppressed |
| Eliquis | Apixaban | 70 | 13 |
| Trulicity | Dulaglutide | 70 | 11 |
| Prednisone | Prednisone | 66 | 57 |
| Jardiance | Empagliflozin | 63 | 14 |
| Telmisartan | Telmisartan | 58 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 14 |
| Ezetimibe | Ezetimibe | 52 | 16 |
| Atenolol | Atenolol | 49 | 11 |
| Famotidine | Famotidine | 47 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 15 |
| Spironolactone | Spironolactone | 44 | suppressed |
| Celecoxib | Celecoxib | 42 | 13 |
| Bupropion Xl | Bupropion Hcl | 41 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 38 | 13 |
| Tramadol Hcl | Tramadol Hcl | 37 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Ozempic | Semaglutide | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | 13 |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Constulose | Lactulose | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 12 |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 14 |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 14 |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 13 |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $641.20 · 32 records | ABBVIE INC. | AIRSUPRA, Dexcom G6 Transmitter, Exablate, Freelite, Gamunex-C, HADLIMA, Hizentra, INCEPTIV, INGREZZA, JATENZO, Leqembi, NURTEC ODT, OTEZLA, PRECIVITYAD2, REPATHA, REZDIFFRA, Rystiggo, SKYRIZI, Tymlos, VOQUEZNA, VYEPTI, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error